RT info:eu-repo/semantics/article
T1 In vitro and in vivo evaluation of first-generation carbosilane arene Ru(II)-metallodendrimers in advanced prostate cancer
A1 Maroto Díaz, Marta
A1 Sanz del Olmo, Natalia
A1 Muñoz Moreno, Laura
A1 Bajo Chueca, Ana María
A1 Carmena Sierra, María José
A1 Gómez Ramírez, Rafael
A1 García Gallego, Sandra
A1 Mata de la Mata, Francisco Javier de la
K1 Dendrimer
K1 Metallodendrimer
K1 Ruthenium
K1 Cancer therapy
K1 Prostate cancer
K1 Química
K1 Chemistry
AB Background. Prostate cancer is the fifth cause of death among men worldwide. Patients suffering resistant prostate tumor, unresponsive to common treatments, can only be treated with palliative therapy. Materials and methods. Ruthenium(II) carbosilane metallodendrimers containing arene moieties were evaluated as a novel antitumor nanotherapy against resistant prostate cancer. The preclinical evaluation included relevant in vitro, ex vivo and in vivo assays, in an experimental mice model of human prostate cancer. Results. Promising cytotoxic, antiproliferative and antimetastatic behaviors were observed. After treatment with these nanocompounds, mice underwent a significant reduction of tumor volume, in comparison to non-treated animals. Conclusions. The selective antitumor behavior and the lack of toxicity, potentially make ruthenium(II) metallodendrimers promising agents for cancer therapy.
SN 0014-3057
YR 2019
FD 2019-04
LK http://hdl.handle.net/10017/46748
UL http://hdl.handle.net/10017/46748
LA eng
NO Ministerio de Industria, Economía y Competitividad
DS MINDS@UW
RD 25-abr-2024